SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,124,719 | -59.1% | 77,460 | -41.0% | 0.00% | -100.0% |
| Q2 2023 | $2,748,737 | +19.6% | 131,330 | +20.7% | 0.00% | 0.0% |
| Q1 2023 | $2,298,278 | -17.0% | 108,820 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $2,769,469 | +5.9% | 108,820 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $2,615,000 | +220.5% | 108,820 | +156.7% | 0.00% | – |
| Q2 2022 | $816,000 | +45.5% | 42,400 | +31.3% | 0.00% | – |
| Q1 2022 | $561,000 | -20.4% | 32,300 | +0.3% | 0.00% | – |
| Q4 2021 | $705,000 | +14.6% | 32,200 | 0.0% | 0.00% | – |
| Q3 2021 | $615,000 | +11.2% | 32,200 | 0.0% | 0.00% | – |
| Q2 2021 | $553,000 | -10.1% | 32,200 | +17.1% | 0.00% | – |
| Q1 2021 | $615,000 | +0.5% | 27,500 | 0.0% | 0.00% | – |
| Q4 2020 | $612,000 | +23.1% | 27,500 | -18.4% | 0.00% | – |
| Q3 2020 | $497,000 | -0.4% | 33,700 | 0.0% | 0.00% | – |
| Q2 2020 | $499,000 | +61.0% | 33,700 | +19.1% | 0.00% | – |
| Q1 2020 | $310,000 | +108.1% | 28,300 | +66.5% | 0.00% | – |
| Q4 2019 | $149,000 | +17.3% | 17,000 | 0.0% | 0.00% | – |
| Q3 2019 | $127,000 | -7.3% | 17,000 | +15.6% | 0.00% | – |
| Q2 2019 | $137,000 | +90.3% | 14,700 | +7.3% | 0.00% | – |
| Q1 2019 | $72,000 | +18.0% | 13,700 | 0.0% | 0.00% | – |
| Q4 2018 | $61,000 | -45.0% | 13,700 | 0.0% | 0.00% | – |
| Q3 2018 | $111,000 | +15.6% | 13,700 | 0.0% | 0.00% | – |
| Q2 2018 | $96,000 | -33.8% | 13,700 | +34.3% | 0.00% | – |
| Q1 2018 | $145,000 | +62.9% | 10,200 | 0.0% | 0.00% | – |
| Q4 2017 | $89,000 | – | 10,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |